company background image
ANIK

Anika Therapeutics NasdaqGS:ANIK Stock Report

Last Price

US$31.47

Market Cap

US$459.8m

7D

3.4%

1Y

-20.7%

Updated

01 Dec, 2022

Data

Company Financials +
ANIK fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ANIK Stock Overview

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally.

Rewards

Trading at 59.1% below our estimate of its fair value

Earnings are forecast to grow 91.87% per year

Risk Analysis

No risks detected for ANIK from our risk checks.

Anika Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Anika Therapeutics
Historical stock prices
Current Share PriceUS$31.47
52 Week HighUS$41.19
52 Week LowUS$19.95
Beta0.96
1 Month Change4.80%
3 Month Change38.82%
1 Year Change-20.69%
3 Year Change-44.84%
5 Year Change-40.61%
Change since IPO799.14%

Recent News & Updates

Recent updates

Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?

Jun 25
Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?

How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

Mar 16
How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly

Feb 09
Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly

An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued

Jan 13
An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued

If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%

Dec 18
If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%

Shareholder Returns

ANIKUS BiotechsUS Market
7D3.4%2.7%1.4%
1Y-20.7%-10.3%-16.1%

Return vs Industry: ANIK underperformed the US Biotechs industry which returned -10.2% over the past year.

Return vs Market: ANIK underperformed the US Market which returned -14.8% over the past year.

Price Volatility

Is ANIK's price volatile compared to industry and market?
ANIK volatility
ANIK Average Weekly Movement6.9%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: ANIK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: ANIK's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1983297Cheryl Blanchardhttps://www.anikatherapeutics.com

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products.

Anika Therapeutics, Inc. Fundamentals Summary

How do Anika Therapeutics's earnings and revenue compare to its market cap?
ANIK fundamental statistics
Market CapUS$459.77m
Earnings (TTM)-US$15.74m
Revenue (TTM)US$152.44m

3.0x

P/S Ratio

-29.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ANIK income statement (TTM)
RevenueUS$152.44m
Cost of RevenueUS$62.19m
Gross ProfitUS$90.25m
Other ExpensesUS$105.99m
Earnings-US$15.74m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.08
Gross Margin59.20%
Net Profit Margin-10.33%
Debt/Equity Ratio0%

How did ANIK perform over the long term?

See historical performance and comparison